112 related articles for article (PubMed ID: 21087977)
1. Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome.
; Yamaguchi K; Shijubo N; Kodama T; Mori K; Sugiura T; Kuriyama T; Kawahara M; Shinkai T; Iguchi H; Sakurai M
Jpn J Clin Oncol; 2011 Jan; 41(1):148-52. PubMed ID: 21087977
[TBL] [Abstract][Full Text] [Related]
2. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
Wong F; Blei AT; Blendis LM; Thuluvath PJ
Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.
Soupart A; Coffernils M; Couturier B; Gankam-Kengne F; Decaux G
Clin J Am Soc Nephrol; 2012 May; 7(5):742-7. PubMed ID: 22403276
[TBL] [Abstract][Full Text] [Related]
4. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
Decaux G
J Lab Clin Med; 2001 Jul; 138(1):18-21. PubMed ID: 11433224
[TBL] [Abstract][Full Text] [Related]
5. [Vasopressin antagonist in hyponatremia. Rapid and simple control of serum sodium concentration].
MMW Fortschr Med; 2012 Dec; 154(22):78-9. PubMed ID: 23297546
[No Abstract] [Full Text] [Related]
6. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.
Soupart A; Gross P; Legros JJ; Alföldi S; Annane D; Heshmati HM; Decaux G
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1154-60. PubMed ID: 17699341
[TBL] [Abstract][Full Text] [Related]
7. Treatment options for hyponatremia in heart failure.
Goldsmith SR
Congest Heart Fail; 2010 Jul; 16 Suppl 1():S15-8. PubMed ID: 20653706
[TBL] [Abstract][Full Text] [Related]
8. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.
Gargani L; Schmidt PH; Gheorghiade M
Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1505-13. PubMed ID: 22103869
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
10. Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders.
Josiassen RC; Curtis J; Filmyer DM; Audino B; Skuban N; Shaughnessy RA
Expert Opin Pharmacother; 2010 Mar; 11(4):637-48. PubMed ID: 20163274
[TBL] [Abstract][Full Text] [Related]
11. [Aquaretic drugs--a new therapeutic principle in treatment of hyponatremia?].
Hensen J; Buchfelder M; Gross P
Fortschr Med; 1997 Jun; 115(17):46-50. PubMed ID: 9312543
[TBL] [Abstract][Full Text] [Related]
12. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
Palm C; Pistrosch F; Herbrig K; Gross P
Am J Med; 2006 Jul; 119(7 Suppl 1):S87-92. PubMed ID: 16843091
[TBL] [Abstract][Full Text] [Related]
13. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
Velez JC; Dopson SJ; Sanders DS; Delay TA; Arthur JM
Nephrol Dial Transplant; 2010 May; 25(5):1524-31. PubMed ID: 20064953
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
[TBL] [Abstract][Full Text] [Related]
15. Small cell gall bladder carcinoma complicated by syndrome of inappropriate secretion of antidiuretic hormone (SIADH) treated with mozavaptan.
Tamura T; Takeuchi K
BMJ Case Rep; 2013 Jun; 2013():. PubMed ID: 23761568
[TBL] [Abstract][Full Text] [Related]
16. [Syndrome of inappropriate ADH secretion (SIADH) in small-cell bronchus carcinoma].
von Rohr A; Cerny T; Joss RA; Brunner KW
Schweiz Med Wochenschr; 1991 Sep; 121(36):1271-82. PubMed ID: 1656520
[TBL] [Abstract][Full Text] [Related]
17. Inappropriate secretion of antidiuretic hormone in nude mice bearing a human bronchogenic oat cell carcinoma.
Kondo Y; Mizumoto Y; Katayama S; Murase T; Yamaji T; Ohsawa N; Kosaka K
Cancer Res; 1981 Apr; 41(4):1545-8. PubMed ID: 6260343
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.
Bordi P; Tiseo M; Buti S; Regolisti G; Ardizzoni A
Tumori; 2015 Apr; 101(2):e51-3. PubMed ID: 25702667
[TBL] [Abstract][Full Text] [Related]
19. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
Ali F; Raufi MA; Washington B; Ghali JK
Cardiovasc Drug Rev; 2007; 25(3):261-79. PubMed ID: 17919259
[TBL] [Abstract][Full Text] [Related]
20. Tolvaptan (Samsca) for hyponatremia.
Med Lett Drugs Ther; 2009 Nov; 51(1326):95-6. PubMed ID: 20224525
[No Abstract] [Full Text] [Related]
[Next] [New Search]
